S 832 119th Congress Senate Health

EPIC Act of 2025

Introduced: March 4, 2025 Introduced by: Tillis, Thomas Republican · North Carolina See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 4, 2025

Read twice and referred to the Committee on Finance.

Mar 4, 2025

Introduced in Senate

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Plain-English summary Congressional Research Service

Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.

What's happening now March 4, 2025

Read twice and referred to the Committee on Finance.

Bill text 1 version

Introduced in Senate Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Finance Committee
Senate

Lobbying activity 165

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

GSK (FKA GLAXOSMITHKLINE INC.)
for GSK (FKA GLAXOSMITHKLINE INC.) · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2026
LUNDBECK LLC
for LUNDBECK LLC · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2026
LMH STRATEGIC SOLUTIONS
for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2026
HARNED STRATEGIES LLC
for JOB CREATORS NETWORK · Texas · 2nd Quarter (Apr 1 - June 30) 2026
SOLENO THERAPEUTICS, INC.
for SOLENO THERAPEUTICS, INC. · California · 1st Quarter (Jan 1 - Mar 31) 2026
SOLENO THERAPEUTICS, INC.
for SOLENO THERAPEUTICS, INC. · California · 1st Quarter (Jan 1 - Mar 31) 2026